US03528H1095 - Common Stock
ANIXA BIOSCIENCES INC
NASDAQ:ANIX (4/26/2024, 1:56:04 PM)
3.22
+0.24 (+8.05%)
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The firm's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118
P: 14087089808
CEO: Amit Kumar
Employees: 4
Website: https://www.anixa.com/
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
Anixa Biosciences (ANIX) said that its collaborator, Cleveland Clinic, has received a Japanese patent for its ovarian cancer vaccine technology. The technology
Here you can normally see the latest stock twits on ANIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: